BIOGEN IDEC - Dominating Multiple Sclerosis Market for Long Term!
Delay in FDA action – review on the inclusion of anti-JC virus – REMS programs for Tysabri, was offset by the data presented at ECTRIMS ‘11 on BG-12 and Daclizumab (stock up by 6-8%). We expect the earnings also to please investors and with a robust cash position (total cash: $2.1b and yearly FCF of ~$1.3b), and with Tysabri, Famprya, BG-12 (PhIII), Daclizumab (PhII), PEG-IFN b-1a (PhIII), BIIB should retain its leadership in the MS space. For more detail, please read our report released on 25th October, 2011 on BIIB titled “Dominating Multiple Sclerosis Market for Long Term!”
COMPANIES MENTIONED
BIOGEN IDEC
BIOGEN IDEC
